{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:19:37Z","timestamp":1783376377664,"version":"3.54.6"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00890-7","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:15:43Z","timestamp":1742202943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1186","volume":"26","author":[{"given":"ZeHu","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QiFeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiuMing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiXia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"890_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.ajkd.2021.09.029","volume":"80","author":"JE Novak","year":"2022","unstructured":"Novak JE, Ellison DH. Diuretics in States of volume overload: core curriculum 2022. Am J Kidney Dis. 2022;80:264\u201376.","journal-title":"Am J Kidney Dis"},{"key":"890_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/ejhf.3179","volume":"26","author":"J Ezekowitz","year":"2024","unstructured":"Ezekowitz J, Alemayehu W, Edelmann F, Ponikowski P, Lam CSP, O\u2019Connor CM, et al. Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: insights from the VICTORIA trial. Eur J Heart Fail. 2024;26:628\u201337.","journal-title":"Eur J Heart Fail"},{"key":"890_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","volume":"26","author":"TA McDonagh","year":"2024","unstructured":"Authors\/Task Force Members, McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2024;26:5\u201317.","journal-title":"Eur J Heart Fail"},{"key":"890_CR4","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation. 2022;145:e895\u20131032.","journal-title":"Circulation"},{"key":"890_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11897-024-00643-3","volume":"21","author":"JJ Cuthbert","year":"2024","unstructured":"Cuthbert JJ, Clark AL. Diuretic treatment in patients with heart failure: current evidence and future Directions \u2013 Part I: loop diuretics. Curr Heart Fail Rep. 2024;21:101\u201314.","journal-title":"Curr Heart Fail Rep"},{"key":"890_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/pharmaceutics10010036","volume":"10","author":"ES Mohn","year":"2018","unstructured":"Mohn ES, Kern HJ, Saltzman E, Mitmesser SH, McKay DL. Evidence of Drug\u2013Nutrient interactions with chronic use of commonly prescribed medications: an update. Pharmaceutics. 2018;10:36.","journal-title":"Pharmaceutics"},{"key":"890_CR7","doi-asserted-by":"publisher","first-page":"13989","DOI":"10.1038\/s41598-023-41095-4","volume":"13","author":"T Hirai","year":"2023","unstructured":"Hirai T, Kondo Y, Sakazaki Y, Seki A, Ishitsuka Y, Iwamoto T. Drug-drug interaction signals between loop diuretics and Teicoplanin during acute kidney injury evaluated using Japanese spontaneous adverse drug event reports. Sci Rep. 2023;13:13989.","journal-title":"Sci Rep"},{"key":"890_CR8","doi-asserted-by":"publisher","first-page":"C843","DOI":"10.1152\/ajpcell.00144.2019","volume":"317","author":"L Kelly","year":"2019","unstructured":"Kelly L, Almutairi MM, Kursan S, Pacheco R, Dias-Junior E, Castrop H, et al. Impaired glucose tolerance, glucagon, and insulin responses in mice lacking the loop diuretic-sensitive Nkcc2a transporter. Am J Physiol Cell Physiol. 2019;317:C843\u201356.","journal-title":"Am J Physiol Cell Physiol"},{"key":"890_CR9","doi-asserted-by":"crossref","unstructured":"Abulatan IT, Ben-David SG, Morales-Colon LA, Beason E, Fakoya AO. A compilation of drug etiologies of Stevens-Johnson syndrome and toxic epidermal necrolysis. Cureus. 2023;15:e48728.","DOI":"10.7759\/cureus.48728"},{"key":"890_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2174\/1389200223666220401092112","volume":"23","author":"NMP Maideen","year":"2022","unstructured":"Maideen NMP, Balasubramanian R, Muthusamy S. A comprehensive review of the Pharmacologic perspective on loop diuretic drug interactions with therapeutically used drugs. Curr Drug Metab. 2022;23:188\u201399.","journal-title":"Curr Drug Metab"},{"key":"890_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/gerona\/glz166","volume":"75","author":"Y Joo","year":"2020","unstructured":"Joo Y, Cruickshanks KJ, Klein BEK, Klein R, Hong O, Wallhagen MI. The contribution of ototoxic medications to hearing loss among older adults. J Gerontol Biol Sci Med Sci. 2020;75:561\u20136.","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"890_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11897-024-00644-2","volume":"21","author":"JJC J G F C","year":"2024","unstructured":"J G F C JJC. Diuretic treatment in patients with heart failure: current evidence and future Directions-Part II: combination therapy. Curr Heart Fail Rep. 2024;21:115\u201330.","journal-title":"Curr Heart Fail Rep"},{"key":"890_CR13","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","volume":"75","author":"GM Felker","year":"2020","unstructured":"Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure: JACC State-of-the-Art review. J Am Coll Cardiol. 2020;75:1178\u201395.","journal-title":"J Am Coll Cardiol"},{"key":"890_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S1388-9842(02)00122-8","volume":"4","author":"J Cos\u00edn","year":"2002","unstructured":"Cos\u00edn J, D\u00edez J. TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4:507\u201313.","journal-title":"Eur J Heart Fail"},{"key":"890_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamacardio.2023.4776","volume":"9","author":"SR Krim","year":"2024","unstructured":"Krim SR, Anand S, Greene SJ, Chen A, Wojdyla D, Vilaro J, et al. Torsemide vs Furosemide among patients with New-Onset vs worsening chronic heart failure: A substudy of the TRANSFORM-HF randomized clinical trial. JAMA Cardiol. 2024;9:182\u20138.","journal-title":"JAMA Cardiol"},{"key":"890_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796\u2013803.","journal-title":"Int J Med Sci"},{"key":"890_CR17","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1097\/JS9.0000000000002194","volume":"111","author":"H Liu","year":"2025","unstructured":"Liu H, Yang Q, Li Z, Yan S, Ming S. Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database. Int J Surg. 2025;111:1988\u201394.","journal-title":"Int J Surg"},{"key":"890_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement. Drug Saf. 2024;47:575\u201384.","journal-title":"Drug Saf"},{"key":"890_CR19","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","volume":"15","author":"F Zou","year":"2024","unstructured":"Zou F, Cui Z, Lou S, Ou Y, Zhu C, Shu C, et al. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol. 2024;15:1338902.","journal-title":"Front Pharmacol"},{"key":"890_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"890_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"890_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W Dumouchel","year":"1999","unstructured":"Dumouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53:177\u201390.","journal-title":"Am Stat"},{"key":"890_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02248-3","author":"X Zhang","year":"2024","unstructured":"Zhang X, Jiang Y, Guo Y, Zhou W, Qiao W, Zhu H, et al. Safety evaluation of Ceftazidime\/avibactam based on FAERS database. Infection. 2024. https:\/\/doi.org\/10.1007\/s15010-024-02248-3.","journal-title":"Infection"},{"key":"890_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jamda.2013.02.002","volume":"14","author":"M Wehling","year":"2013","unstructured":"Wehling M. Morbus diureticus in the elderly: epidemic overuse of a widely applied group of drugs. J Am Med Dir Assoc. 2013;14:437\u201342.","journal-title":"J Am Med Dir Assoc"},{"key":"890_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03615-5","author":"L Schr\u00f6der","year":"2024","unstructured":"Schr\u00f6der L, Seifert R. The 10 top prescribed medicines in Germany from 1985 to 2022: Pharmacological analysis. Naunyn Schmiedebergs Arch Pharmacol. 2024. https:\/\/doi.org\/10.1007\/s00210-024-03615-5.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"890_CR26","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(09)61460-4","volume":"374","author":"K Christensen","year":"2009","unstructured":"Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009;374:1196\u2013208.","journal-title":"Lancet"},{"key":"890_CR27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1046\/j.1365-2133.1998.02146.x","volume":"138","author":"S Boulinguez","year":"1998","unstructured":"Boulinguez S, Bernard P, Bedane C, le Brun V, Bonnetblanc JM. Bullous pemphigoid induced by bumetanide. Br J Dermatol. 1998;138:548\u20139.","journal-title":"Br J Dermatol"},{"key":"890_CR28","first-page":"e20647","volume":"13","author":"AB Ambur","year":"2021","unstructured":"Ambur AB, Nathoo R, Saeed S. A case of Drug-Induced bullous pemphigoid with an isomorphic response and updated review of koebnerization in bullous diseases. Cureus. 2021;13:e20647.","journal-title":"Cureus"},{"key":"890_CR29","first-page":"562","volume":"5","author":"JJ Lee","year":"2006","unstructured":"Lee JJ, Downham TF. Furosemide-induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol. 2006;5:562\u20134.","journal-title":"J Drugs Dermatol"},{"key":"890_CR30","doi-asserted-by":"publisher","first-page":"16786","DOI":"10.3390\/ijms242316786","volume":"24","author":"B de Nicolas-Ruanes","year":"2023","unstructured":"de Nicolas-Ruanes B, Ballester-Martinez A, Garcia-Mouronte E, Berna-Rico E, Azcarraga-Llobet C, Fernandez-Guarino M. From molecular insights to clinical perspectives in Drug-Associated bullous pemphigoid. Int J Mol Sci. 2023;24:16786.","journal-title":"Int J Mol Sci"},{"key":"890_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/2013.jamadermatol.376","volume":"149","author":"A Lloyd-Lavery","year":"2013","unstructured":"Lloyd-Lavery A, Chi C-C, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol. 2013;149:58\u201362.","journal-title":"JAMA Dermatol"},{"key":"890_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1742-1241.1997.tb09626.x","volume":"51","author":"BN Panayiotou","year":"1997","unstructured":"Panayiotou BN, Prasad MV, Zaman MN. Frusemide-induced bullous pemphigoid. Br J Clin Pract. 1997;51:49\u201350.","journal-title":"Br J Clin Pract"},{"key":"890_CR33","doi-asserted-by":"publisher","first-page":"26663","DOI":"10.2340\/actadv.v104.26663","volume":"104","author":"D SHALMON","year":"2024","unstructured":"Shalmon D, Bar-Ilan E, Peled A, Geller S, Bar J, Schwartz N, et al. Identification of risk factors for Gliptin-associated bullous pemphigoid among diabetic patients. Acta Derm Venereol. 2024;104:26663.","journal-title":"Acta Derm Venereol"},{"key":"890_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/nyas.14536","volume":"1498","author":"TJ Smith","year":"2021","unstructured":"Smith TJ, Johnson CR, Koshy R, Hess SY, Qureshi UA, Mynak ML, et al. Thiamine deficiency disorders: a clinical perspective. Ann N Y Acad Sci. 2021;1498:9\u201328.","journal-title":"Ann N Y Acad Sci"},{"key":"890_CR35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/cvr\/14.9.537","volume":"14","author":"Y Yui","year":"1980","unstructured":"Yui Y, Itokawa Y, Kawai C. Furosemide-induced thiamine deficiency. Cardiovasc Res. 1980;14:537\u201340.","journal-title":"Cardiovasc Res"},{"key":"890_CR36","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0022-2143(99)90203-2","volume":"134","author":"J Rieck","year":"1999","unstructured":"Rieck J, Halkin H, Almog S, Seligman H, Lubetsky A, Olchovsky D, et al. Urinary loss of thiamine is increased by low doses of Furosemide in healthy volunteers. J Lab Clin Med. 1999;134:238\u201343.","journal-title":"J Lab Clin Med"},{"key":"890_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0002-9343(91)90007-K","volume":"91","author":"H Seligmann","year":"1991","unstructured":"Seligmann H, Halkin H, Rauchfleisch S, Kaufmann N, Motro M, Vered Z, et al. Thiamine deficiency in patients with congestive heart failure receiving long-term Furosemide therapy: a pilot study. Am J Med. 1991;91:151\u20135.","journal-title":"Am J Med"},{"key":"890_CR38","first-page":"184","volume":"10","author":"C Zenuk","year":"2003","unstructured":"Zenuk C, Healey J, Donnelly J, Vaillancourt R, Almalki Y, Smith S. Thiamine deficiency in congestive heart failure patients receiving long term Furosemide therapy. Can J Clin Pharmacol. 2003;10:184\u20138.","journal-title":"Can J Clin Pharmacol"},{"key":"890_CR39","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.clnu.2016.02.011","volume":"35","author":"LM Teigen","year":"2016","unstructured":"Teigen LM, Twernbold DD, Miller WL. Prevalence of thiamine deficiency in a stable heart failure outpatient cohort on standard loop diuretic therapy. Clin Nutr. 2016;35:1323\u20137.","journal-title":"Clin Nutr"},{"key":"890_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.genhosppsych.2024.01.005","volume":"87","author":"A Cantu-Weinstein","year":"2024","unstructured":"Cantu-Weinstein A, Branning R, Alamir M, Weleff J, Do M, Nero N, et al. Diagnosis and treatment of Wernicke\u2019s encephalopathy: A systematic literature review. Gen Hosp Psychiatry. 2024;87:48\u201359.","journal-title":"Gen Hosp Psychiatry"},{"key":"890_CR41","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJM197803302981315","volume":"298","author":"EB Flink","year":"1978","unstructured":"Flink EB. Role of magnesium depletion in Wernicke-Korsakoff syndrome. N Engl J Med. 1978;298:743\u20134.","journal-title":"N Engl J Med"},{"key":"890_CR42","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/S0140-6736(99)00182-8","volume":"353","author":"J McLean","year":"1999","unstructured":"McLean J, Manchip S. Wernicke\u2019s encephalopathy induced by magnesium depletion. Lancet. 1999;353:1768.","journal-title":"Lancet"},{"key":"890_CR43","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s10072-017-3062-y","volume":"38","author":"D Baroncini","year":"2017","unstructured":"Baroncini D, Annovazzi P, Minonzio G, Franzetti I, Zaffaroni M. Hypomagnesaemia as a trigger of relapsing non-alcoholic Wernicke encephalopathy: a case report. Neurol Sci. 2017;38:2069\u201371.","journal-title":"Neurol Sci"},{"key":"890_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/hrt.57.1.17","volume":"57","author":"J Bayliss","year":"1987","unstructured":"Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17\u201322.","journal-title":"Br Heart J"},{"key":"890_CR45","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/ehf2.14277","volume":"10","author":"S Kawanami","year":"2022","unstructured":"Kawanami S, Egami Y, Sugae H, Ukita K, Kawamura A, Nakamura H, et al. Predictors of bleeding events in acute decompensated heart failure patients with antithrombotic therapy: AURORA study. ESC Heart Fail. 2022;10:1114\u201321.","journal-title":"ESC Heart Fail"},{"key":"890_CR46","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.healun.2016.12.016","volume":"36","author":"BA Houston","year":"2017","unstructured":"Houston BA, Schneider ALC, Vaishnav J, Cromwell DM, Miller PE, Faridi KF, et al. Angiotensin II antagonism is associated with reduced risk for Gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. J Heart Lung Transpl. 2017;36:380\u20135.","journal-title":"J Heart Lung Transpl"},{"key":"890_CR47","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.burns.2019.10.008","volume":"46","author":"L Yang","year":"2020","unstructured":"Yang L, Shou Y-H, Li F, Zhu X-H, Yang Y-S, Xu J-H. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China. Burns. 2020;46:959\u201369.","journal-title":"Burns"},{"key":"890_CR48","doi-asserted-by":"crossref","unstructured":"Reddy S, Aron BK, Stewart J. A Life-Threatening case of Torsemide-Induced toxic epidermal necrolysis associated with the treatment of Anasarca. Cureus. 2022;14:e22895.","DOI":"10.7759\/cureus.22895"},{"key":"890_CR49","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2165\/00003495-198428050-00003","volume":"28","author":"A Ward","year":"1984","unstructured":"Ward A, Heel RC, Bumetanide. A review of its pharmacodynamic and Pharmacokinetic properties and therapeutic use. Drugs. 1984;28:426\u201364.","journal-title":"Drugs"},{"key":"890_CR50","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jaip.2017.02.018","volume":"5","author":"A Banerji","year":"2017","unstructured":"Banerji A, Blumenthal KG, Lai KH, Zhou L. Epidemiology and incidence of ACE inhibitor angioedema utilizing a large electronic health record. J Allergy Clin Immunol Pract. 2017;5:744\u20139.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"890_CR51","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.iac.2022.01.004","volume":"42","author":"F Bassir","year":"2022","unstructured":"Bassir F, Varghese S, Wang L, Chin YP, Zhou L. The use of electronic health records to study Drug-Induced hypersensitivity reactions from 2000 to 2021: A systematic review. Immunol Allergy Clin North Am. 2022;42:453\u201397.","journal-title":"Immunol Allergy Clin North Am"},{"key":"890_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/12034754231220931","volume":"28","author":"H Godfrey","year":"2024","unstructured":"Godfrey H, Jedlowski P, Thiede R. Medication associations with severe cutaneous adverse reactions: A Case\/Non-Case analysis using the FDA adverse event reporting system. J Cutan Med Surg. 2024;28:51\u20138.","journal-title":"J Cutan Med Surg"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00890-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00890-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00890-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:25:10Z","timestamp":1742203510000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00890-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["890"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00890-7","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anonymized data were collected from a publicly available database (FAERS database, ), the need for ethics approval and consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}